Michael R Bristow

List of Publications by Year
in descending order

74 papers	9,954 citations	147801 31 h-index	95266 68 g-index
77 all docs	77 docs citations	77 times ranked	8586 citing authors

#	Article	IF	Citations
1	Integrated analysis of miRNAâ€“mRNA interaction in pediatric dilated cardiomyopathy. Pediatric Research, 2022, 92, 98-108.	2.3	12
2	An LMNA synonymous variant associated with severe dilated cardiomyopathy: Case report. American Journal of Medical Genetics, Part A, 2022, 188, 600-605.	1.2	1
3	Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. American Heart Journal, 2022, 246, 136-143.	2.7	8
4	lncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth. Circulation, 2022, 145, 1218-1233.	1.6	43
5	Cardiac Adrenergic Activation in Heart Failure With Preserved Ejection Fraction. JACC Basic To Translational Science, 2022, 7, 128-130.	4.1	1
6	Activation of PDGFRA signaling contributes to filamin Câ€“related arrhythmogenic cardiomyopathy. Science Advances, 2022, 8, eabk0052.	10.3	12
7	Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes Enables Modeling of Human Hypertrophic Cardiomyopathy. Stem Cell Reports, 2021, 16, 519-533.	4.8	33
8	The Essential Vulnerability of Human Cardiac Myocytes to SARS-CoV-2. JACC Basic To Translational Science, 2021, 6, 346-349.	4.1	4
9	COVID-19 and Cardiovascular Disease. Circulation Research, 2021, 128, 1214-1236.	4.5	232
10	Abstract 079: Nebivolol Associated With Reduced Incident Cardiovascular Events In Hypertensive Patients Compared With Non-vasodilatory Beta Blockers. Circulation, 2021, 143, .	1.6	1
11	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. Circulation: Heart Failure, 2021, 14, .	3.9	11
12	The Addition of a Defibrillator toÂResynchronization Therapy DecreasesÂMortality in Patients With Nonischemic Cardiomyopathy. JACC: Heart Failure, 2021, 9, 439-449.	4.1	10
13	Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009591.	4.8	5
14	Serum response factor deletion 5 regulates phospholamban phosphorylation and calcium uptake. Journal of Molecular and Cellular Cardiology, 2021, 159, 28-37.	1.9	1
15	Dynamic Regulation of SARS-Cov-2 Binding and Cell Entry Mechanisms in Remodeled Human Ventricular Myocardium. JACC Basic To Translational Science, 2020, 5, 871-883.	4.1	51
16	Transcriptome signature of ventricular arrhythmia in dilated cardiomyopathy reveals increased fibrosis and activated TP53. Journal of Molecular and Cellular Cardiology, 2020, 139, 124-134.	1.9	17
17	Sequential analysis of myocardial gene expression with phenotypic change: Use of cross-platform concordance to strengthen biologic relevance. PLoS ONE, 2019, 14, e0221519.	2.5	8
18	Impact of Degree of Left Ventricular Remodeling on Clinical Outcomes From Cardiac Resynchronization Therapy. JACC: Heart Failure, 2019, 7, 281-290.	4.1	2

#	Article	IF	Citations
19	Filamin C Truncation Mutations Are Associated With Arrhythmogenic DilatedÂCardiomyopathy and Changes inÂthe Cellâ€“Cell Adhesion Structures. JACC: Clinical Electrophysiology, 2018, 4, 504-514.	3.2	125
20	Contractile reserve and the response to cardiac resynchronization therapy. International Journal of Cardiology, 2018, 252, 234-235.	1.7	0
21	Changing the Research Culture in the United States. JACC: Heart Failure, 2018, 6, 344-345.	4.1	4
22	Transcriptome analysis of human heart failure reveals dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart failure. BMC Genomics, 2018, 19, 812.	2.8	150
23	Histamine H2 Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	13
24	Entrepreneurialism in the TranslationalÂBiologic Sciences. JACC Basic To Translational Science, 2018, 3, 1-8.	4.1	0
25	Association of Variants in BAG3 With Cardiomyopathy Outcomes in African American Individuals. JAMA Cardiology, 2018, 3, 929.	6.1	57
26	Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in <scp>TOPCAT</scp>. European Journal of Heart Failure, 2017, 19, 457-465.	7.1	14
27	Genetic variation expressed in the brain may impact heart failure. European Journal of Heart Failure, 2017, 19, 324-325.	7.1	1
28	Outcomes of cardiac resynchronization therapy in patients with intermittent atrial fibrillation or atrial flutter in the COMPANION trial. Heart Rhythm, 2017, 14, 858-865.	0.7	26
29	Structural and Functional Phenotyping of the Failing Heart. JACC: Heart Failure, 2017, 5, 772-781.	4.1	53
30	Heart Rate in Preserved EjectionÂFractionÂHeart Failure. JACC: Heart Failure, 2017, 5, 792-794.	4.1	4
31	Myocardial microRNAs associated with reverse remodeling in human heart failure. JCI Insight, 2017, 2, e89169.	5.0	42
32	Fine Tuning Adenylyl Cyclase as a (Gene)ÂTherapy for Heart Failure. JACC Basic To Translational Science, 2016, 1, 630-632.	4.1	1
33	Detection and Management of Geographic Disparities in the TOPCAT Trial. JACC Basic To Translational Science, 2016, 1, 180-189.	4.1	50
34	Sex-related differences in age-associated downregulation of human ventricular myocardial Î²1-adrenergic receptors. Journal of Heart and Lung Transplantation, 2016, 35, 352-361.	0.6	20
35	Lessons Learned and Insights Gained inÂtheÂDesign, Analysis, and Outcomes ofÂthe COMPANION Trial. JACC: Heart Failure, 2016, 4, 521-535.	4.1	14
36	Histamine H 2 Receptor Antagonists, LeftÂVentricular Morphology, and HeartÂFailureÂRisk. Journal of the American College of Cardiology, 2016, 67, 1544-1552.	2.8	54

#	Article	IF	Citations
37	The Adrenergic System in Pulmonary Arterial Hypertension: Bench to Bedside (2013 Grover Conference) Tj ETQq1 1 0.784314 rgBT /Ove	1.7	16
38	Therapeutic Molecular Phenotype of Î²-Blockerâ€“Associated Reverse-Remodeling in Nonischemic Dilated Cardiomyopathy. Circulation: Cardiovascular Genetics, 2015, 8, 270-283.	5.1	40
39	Cardiovascular Drug Development. Journal of the American College of Cardiology, 2015, 65, 1567-1582.	2.8	168
40	Visual analysis of biological data-knowledge networks. BMC Bioinformatics, 2015, 16, 135.	2.6	29
41	PEAX: INTERACTIVE VISUAL ANALYSIS AND EXPLORATION OF COMPLEX CLINICAL PHENOTYPE AND GENE EXPRESSION ASSOCIATION. , 2014, , .		4
42	Polymorphic Variation in the G-Protein Beta-3 Subunit Gene and Response to BiDil in A-HeFT. JACC: Heart Failure, 2014, 2, 558-560.	4.1	1
43	Race, Common Genetic Variation, and Therapeutic Response Disparities in Heart Failure. JACC: Heart Failure, 2014, 2, 561-572.	4.1	33
44	New-onset Atrial Fibrillation Predicts Heart Failure Progression. American Journal of Medicine, 2014, 127, 963-971.	1.5	36
45	Prevention of Atrial Fibrillation by Bucindolol Is Dependent on the Beta 1 389 Arg/Gly Adrenergic Receptor Polymorphism. JACC: Heart Failure, 2013, 1, 338-344.	4.1	43
46	Treatment of the Heart Failure Patient With Atrial Fibrillation. JACC: Heart Failure, 2013, 1, 29-30.	4.1	3
47	Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. European Journal of Heart Failure, 2013, 15, 324-333.	7.1	33
48	Pharmacogenetic targeting of drugs for heart failure. , 2012, 134, 107-115.		14
49	MicroRNA expression in heart failure. FASEB Journal, 2012, 26, 336.3.	0.5	0
50	Temporal analysis of mRNA and miRNA expression in transgenic mice overexpressing Arg- and Gly389 polymorphic variants of the Î²₁-adrenergic receptor. Physiological Genomics, 2011, 43, 1294-1306.	2.3	17
51	Treatment of Chronic Heart Failure With Î²-Adrenergic Receptor Antagonists. Circulation Research, 2011, 109, 1176-1194.	4.5	147
52	An Î± 2C -Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the Î²-Blocker Bucindolol in Chronic Heart Failure. Circulation: Heart Failure, 2010, 3, 21-28.	3.9	103
53	The FDA Regulatory Process for Drug and Genetic Diagnostic Test Approvals. Clinical and Translational Science, 2008, 1, 188-189.	3.1	1
54	Alterations in Myocardial Gene Expression as a Basis for Cardiomyopathies and Heart Failure. Novartis Foundation Symposium, 2008, , 73-89.	1.1	2

#	Article	IF	Citations
55	Serial Gene Expression Profiling in the Intact Human Heart. Journal of Heart and Lung Transplantation, 2006, 25, 579-588.	0.6	28
56	The COMET Trial. Congestive Heart Failure, 2005, 11, 39-47.	2.0	3
57	Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure. New England Journal of Medicine, 2004, 350, 2140-2150.	27.0	5,193
58	Selective versus nonselective Î²-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?. Journal of Cardiac Failure, 2003, 9, 444-453.	1.7	72
59	Increased Angiotensin-(1-7)â€“Forming Activity in Failing Human Heart Ventricles. Circulation, 2003, 108, 1707-1712.	1.6	305
60	Angiotensin-(1-7) Formation in the Intact Human Heart. Circulation, 2003, 108, 1679-1681.	1.6	114
61	Myocardial Gene Expression in Dilated Cardiomyopathy Treated with Beta-Blocking Agents. New England Journal of Medicine, 2002, 346, 1357-1365.	27.0	462
62	Of Phospholamban, Mice, and Humans With Heart Failure. Circulation, 2001, 103, 787-788.	1.6	10
63	Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving Î²-blocking agents. Current Cardiology Reports, 2001, 3, 224-231.	2.9	37
64	Myosin Heavy Chain Isoform Expression in the Failing and Nonfailing Human Heart. Circulation Research, 2000, 86, 386-390.	4.5	480
65	What Type of Î²-Blocker Should Be Used to Treat Chronic Heart Failure?. Circulation, 2000, 102, 484-486.	1.6	50
66	Myocardial-Directed Overexpression of the Human Î²1-Adrenergic Receptor in Transgenic Mice. Journal of Molecular and Cellular Cardiology, 2000, 32, 817-830.	1.9	239
67	Î²-Adrenergic Receptor Blockade in Chronic Heart Failure. Circulation, 2000, 101, 558-569.	1.6	953
68	Congestive Heart Failure: Fifty Years of Progress. Circulation, 2000, 102, .	1.6	36
69	Cellular and molecular remodeling in a heart failure model treated with the Î²-blocker carteolol. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 276, H1678-H1690.	3.2	22
70	Angiotensin II Receptors in the Normal and Failing Heart. Heart Failure Reviews, 1999, 3, 199-208.	3.9	3
71	The role of third-generation beta-blocking agents in chronic heart failure. Clinical Cardiology, 1998, 21, I3-I13.	1.8	85
72	Tumor Necrosis Factor-Î± and Cardiomyopathy. Circulation, 1998, 97, 1340-1341.	1.6	60

#	Article	IF	Citations
73	Second- and third-generation beta-blocking drugs in chronic heart failure. Cardiovascular Drugs and Therapy, 1997, 11, 291-296.	2.6	30
74	Dynamic Regulation of SARS-CoV-2 Binding and Cell Entry Mechanisms in Remodeled Human Ventricular Myocardium. SSRN Electronic Journal, 0, , .	0.4	1